Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders.
Joined November 2017
- Tweets248
- Following415
- Followers16.9K
- Likes148
Revive Therapeutics (CSE: RVV, US: RVVTF) Official retweeted
If the Irkutsk researcher died of plague, she was presumably unvaccinated and did not receive antibiotics per protocol. Alternatively, the strain was vaccine-evading and antibiotic-resistant. That seldom occurs naturally. Pneumonic plague is only moderately transmissible.
1/5
Revive Therapeutics is expanding its #Bucillamine strategy across medical countermeasures and rare diseases, with plans to strengthen global IP, pursue additional orphan drug opportunities and explore government and strategic partnerships.
Read more: revivethera.com/2026/09/revi…
#Biotech #Biodefense #RareDisease $RVV.CN $RVVTF
🤖 Made with AI
Revive Therapeutics ($RVV | $RVVTF) outlines its strategy to build a focused biodefence & pandemic preparedness therapeutics portfolio, led by bucillamine.
Following positive DRDC research findings, Revive plans to pursue government-backed development opportunities, expand IP and evaluate complementary therapeutics.
🔗 revivethera.com/2026/08/revi…
#Biodefence #PandemicPreparedness #Bucillamine #Biotech #RVV #RVVTF
Revive Therapeutics reports positive results from its DRDC research study evaluating Bucillamine for nerve agent exposure, supporting its potential as a novel medical countermeasure.
Read the full news: revivethera.com/2026/08/revi…
#ReviveTherapeutics #Bucillamine #Biotech #MedicalCountermeasures #DefenseResearch #Pharma $RVV.CN
🧬 Revive Therapeutics expands its bucillamine strategy beyond infectious diseases into defence, biothreat preparedness, and medical countermeasures.
The Company plans to advance additional preclinical studies, strengthen IP protection, pursue government partnerships, and explore future stockpiling opportunities.
Read more: revivethera.com/2026/05/revi…
$RVV $RVVTF #Biotech #Research #HealthCare #Bucillamine #InfectiousDiseases #Pharmaceuticals #DrugDevelopment #ReviveTherapeutics #MedicalCountermeasures
Revive Therapeutics Strengthens Bucillamine IP Portfolio
Revive Therapeutics expands its #Bucillamine IP with new North American patent filings for nerve agent exposure and a granted Canadian patent for infectious diseases.
revivethera.com/2026/03/revi…
$RVV $RVVTF #Biotech #Research #HealthCare #Bucillamine #InfectiousDiseases #Pharmaceuticals #DrugDevelopment #ReviveTherapeutics #MedicalCountermeasures
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
bit.ly/3YEmRVE
$RVV $RVVTF #Biotech #Research #HealthCare #Bucillamine #InfectiousDiseases #Pharmaceuticals #DrugDevelopment #DRDC #ReviveTherapeutics #RVVTF #RVV #MedicalCountermeasures #LifeSciences #Therapeutics
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
bit.ly/3M00ve2
$RVV $RVVTF #Biotech #Research #HealthCare #Bucillamine #InfectiousDiseases #Pharmaceuticals #DrugDevelopment #DRDC
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
bit.ly/4nm4Vu1
$RVV $RVVTF #Biotech #Research #HealthCare #Bucillamine #InfectiousDiseases #Pharmaceuticals #DrugDevelopment #DRDC #Braininjury
Revive Therapeutics Advances with Next-Generation Bucillamine Development
bit.ly/3Hl9oNf
$RVV $RVVTF #Biotech #Research #HealthCare #Bucillamine #InfectiousDiseases #Pharmaceuticals #DrugDevelopment #FDA
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
bit.ly/3GRYRsz
$RVV $RVVTF #Biotech #Research #HealthCare #NerveAgentTreatment #Pharma #FDA #HealthInnovation #LifeSciences #ClinicalTrials #MedTech #PublicHealth #BioResearch #NerveAgent #Bucillamine #MedicalBreakthrough
Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
bit.ly/3G0XmaS
$RVV $RVVTF #cancer #bucillaminne #Biotech #CancerResearch
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
bit.ly/4ltNeYL
$RVV $RVVTF #DiagnaMed #Acquisition #Hydrogen #Neurology #Mental #ALS #FDA #Antioxidant #Inflammatory #Clinical #Biotechnology
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
bit.ly/41pfHW3
$RVV $RVVTF #DiagnaMed #Acquisition #Hydrogen #Neurology #Mental #ALS #FDA #Antioxidant #Inflammatory #Clinical #Biotechnology
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
bit.ly/3WcZ8ef
$RVV $RVVTF #Bucillamine #InfectiousDiseases #MedicalCountermeasures #RareDisorders #NerveAgent #DRDC #DefenceRDC #FDA #HealthCanada
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
bit.ly/3O1Momt
$RVV $RVVTF #psilocybin #therapy #stroke #treatment #psychedelic #neuroprotection $NUMI $MDMA $CYBN $PHRM $MNMD
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
tinyurl.com/m7x7ytp5
$RVV $RVVTF #Bucillamine #InfectiousDiseases #MedicalCountermeasures #RareDisorders #NerveAgent #DRDC #DefenceRDC #FDA #HealthCanada
Revive Therapeutics (CSE: RVV, US: RVVTF) Official retweeted
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
bit.ly/4e91B0h
$RVV $RVVTF #Bucillamine #InfectiousDiseases #MedicalCountermeasures #RareDisorders #NerveAgent #DRDC #DefenceRDC #FDA #HealthCanada #monkeypox
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
bit.ly/4e91B0h
$RVV $RVVTF #Bucillamine #InfectiousDiseases #MedicalCountermeasures #RareDisorders #NerveAgent #DRDC #DefenceRDC #FDA #HealthCanada #monkeypox
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections
bit.ly/3Xn1NDl
$RVV $RVVTF #Bucillamine #InfectiousDiseases #MedicalCountermeasures #RareDisorders #NerveAgent #DRDC #DefenceRDC #FDA #HealthCanada #monkeypox
